Protica Bio

Immunotherapy-based Diagnostics Platform

Health Tech & Life Sciences
Active
Seed Jerusalem Founded 2021
Total raised
Last: Undisclosed 2022-07
Stage
Seed
Founded
2021
Headcount
4
HQ
Jerusalem
Sector
Health Tech & Life Sciences

About

Protica Bio combines cutting-edge proteomics and machine learning to improve immunotherapy-based clinical decisions and new drug discoveries, with the goal of creating diagnostic capabilities and elevating the response rate for current and future treatments.

The company is utilizing a proprietary platform developed by a leading expert in the field of mass spectrometry from the Weizmann Institute. In addition to laboratory research, the company integrates deep proteomics with machine learning to create diagnostic capabilities and elevate the response rate for current and future treatments.

Funding history · 1 round · — total

2022-07
Undisclosed Undisclosed

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTest Diagnostics & Screening
Technologies
Platforms & InterfacesWebArtificial IntelligenceMachine Learning
Target customers
Healthcare & Life SciencesHealthcareLaboratories
Business model
B2C

Tags

immunotherapypharmaceuticalsmachine-learningcancer-diagnosticstreatmentsdrug-discovery